Clinical Efficacy and Safety Analysis of 1.5% Ruxolitinib Cream in The Treatment of Facial Vitiligo in Adolescents: A Retrospective Study of 74 Cases

This retrospective study evaluates the real-world efficacy and safety of 1.5% ruxolitinib cream in 74 Chinese adolescents (ages 12–18) with facial vitiligo, comparing outcomes between non-segmental (NSV) and segmental (SV) subtypes. Participants applied the cream twice daily for 24 weeks, with efficacy assessed using the Facial Vitiligo Area Scoring Index (F-VASI) at weeks 12 and 24. Results showed significant time-dependent improvement, with higher response rates in progressive, early-stage, and late-onset disease. No statistically significant difference in efficacy was observed between NSV and SV subtypes. Adverse events were mild to moderate, primarily local acneiform eruptions, with no serious events or discontinuations. The study supports topical ruxolitinib as an effective and well-tolerated treatment for adolescent facial vitiligo, highlighting the benefit of early intervention, though larger prospective studies are needed to confirm long-term outcomes.